COVID-19, Acute Lymphoblastic Leukemia, and Down Syndrome: A Short Review and a Case Report

Abstract

SARS-CoV-2 which causes COVID-19 has been a great challenge to treat and deal with; despite strict measures that had been implemented by governments and organizations, worrying rates of morbidity and mortality are still being reported. Although available data have expressed that moderate or even mild forms of the disease are expected amongst most pediatrics cases, minimal data are available on the prognosis and the disease’s complications on the immunocompromised, especially oncology patients. We report a case of relapsed precursor B-cell acute lymphoblastic leukemia of a child with Down syndrome and COVID-19 and outline the treatment regimen that we used.

COVID‐19 in patients with Down syndrome: A systematic review

“…The mean age of the patients was 24.8 years (26 days to 60 years), and 29 of the 55 patients were male (Supporting Information S1: Table ) 13–28 . Comorbid conditions were described for 51 cases.…”

“…The mean age of the patients was 24.8 years (26 days to 60 years), and 29 of the 55 patients were male (Supporting Information S1: Table 1). [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] Comorbid conditions were described for 51 cases. Obesity was the most common comorbid condition reported (49.0%, 25) followed by hypothyroidism (21.6%, 11) (Figure 1, Supporting Information S1: Table 1).…”